Bifidobacterium lactis and bowel habits

What 2 graded rows on bifidobacterium lactis agree on for bowel habits, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Bifidobacterium lactis page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Bifidobacterium lactis page, with its PubMed record.

Supplement

Bifidobacterium lactis Choose another

2 rows · 1,348 people

Split. 1 row found an improvement and 1 had mixed results.

Mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

The best-graded row, grade C, is a randomized trial of 1,248 people (2015) and reported mixed results.

The rows run from 100 to 1,248 people, published from 2011 to 2015: 2 single studies.

1 improved · 1 mixed

Grade CWhole-gut transit time in adults with functional gut symptoms · Improved
RCT · n 100 · 2011 · Adults with functional gastrointestinal symptoms (mean age 44, 64% female)
17.2 billion or 1.8 billion CFU a day · 14 days
Transit time fell from 49 to 21 hours on the high dose and from 60 to 41 hours on the low dose, but not on placebo (43 to 44 hours); eight of nine symptoms fell in frequency on the high dose vs two on placebo. No adverse events.
Row on the Bifidobacterium lactis page · PubMed 21663486 (opens PubMed)
Grade CDefecation frequency and gut comfort in adults with infrequent bowel movements · Mixed
RCT · n 1,248 · 2015 · Healthy adults with low defecation frequency and abdominal discomfort
1 billion or 10 billion CFU a day · 4 weeks
Global relief of abdominal discomfort did not differ and the main responder analysis missed significance (OR 1.31, P=0.071); a stricter responder definition (OR 1.55) and average defecation frequency favoured BB-12. Both doses worked similarly.
Row on the Bifidobacterium lactis page · PubMed 26382580 (opens PubMed)